Abstract
A new class of bisphosphonates containing nitrooxy NO-donor functions has been developed. The products proved to display affinity for hydroxyapatite. Injection of (99m)Tc-labeled derivatives 11 and 18 into male rats showed a preferential accumulation of the compounds in bone as compared to blood and muscles. The products were found to inhibit the differentiation of pre-osteoclasts to functional osteoclasts induced by receptor activator of NF-kappaB ligand (RANKL), through a prevalent NO-dependent mechanism.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Bone Resorption / pathology*
-
Carrier Proteins / pharmacology
-
Cell Differentiation
-
Cell Line
-
Diphosphonates / chemical synthesis*
-
Diphosphonates / chemistry
-
Diphosphonates / pharmacology
-
Durapatite / chemistry
-
Male
-
Membrane Glycoproteins / pharmacology
-
Mice
-
NF-kappa B / metabolism
-
Nitric Oxide Donors / chemical synthesis*
-
Nitric Oxide Donors / chemistry
-
Nitric Oxide Donors / pharmacology
-
Osteoclasts / cytology
-
Osteoclasts / drug effects
-
RANK Ligand
-
Radiopharmaceuticals
-
Rats
-
Receptor Activator of Nuclear Factor-kappa B
-
Sodium Pertechnetate Tc 99m
-
Stem Cells / cytology
-
Stem Cells / drug effects
-
Structure-Activity Relationship
-
Tissue Distribution
Substances
-
Carrier Proteins
-
Diphosphonates
-
Membrane Glycoproteins
-
NF-kappa B
-
Nitric Oxide Donors
-
RANK Ligand
-
Radiopharmaceuticals
-
Receptor Activator of Nuclear Factor-kappa B
-
Tnfrsf11a protein, mouse
-
Tnfsf11 protein, mouse
-
Durapatite
-
Sodium Pertechnetate Tc 99m